Indicated for: breast cancer
Substance: eribulin (antineoplastic agent)
ATC: L01XX41 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)
Eribulin is a chemotherapy medication used in the treatment of certain types of cancer, especially advanced breast cancer or liposarcoma. It works by inhibiting cell division, which stops the growth and multiplication of cancer cells.
Eribulin is administered by intravenous infusion at intervals determined by the oncologist, usually once every few weeks. The dose and frequency of treatment are tailored to each patient, depending on the response to therapy and any associated conditions.
Side effects may include fatigue, nausea, vomiting, decreased blood cell counts, hair loss, or, rarely, severe allergic reactions. Medical monitoring is essential throughout the treatment to manage possible complications.
Eribulin is an important option for patients with advanced cancer, offering the chance to slow disease progression and improve quality of life.